Tirzepatide

Dual amylin and calcitonin receptor agonists (DACRAs) offer a promising strategy for treating obesity and related metabolic disorders but are limited by aggregation and the short half-lives of native peptides. Here, we report the design of a long-act…

BACKGROUND: Bariatric surgery has long been established as an effective treatment option for obesity and diabetes [Kalainov et al. in J Am Acad Orthop Surg [32(10):427-438, 2025] and Ogden et al. in JAMA 311(8):806-806, 2025. 10.1001/jama.2014.732].…

BACKGROUND: Obstructive sleep apnea (OSA) is a highly prevalent and heterogeneous disorder associated with substantial cardiometabolic morbidity. Although continuous positive airway pressure (CPAP) remains first-line therapy, long-term effectiveness…

AIMS: Treatment of obesity with glucagon-like peptide-1 (GLP-1) receptor agonists improves cardiovascular outcomes. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, achieves greater weight loss than GLP-1 r…

AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine-related adverse events (AEs). This study investigated the association bet…

BACKGROUND: Obstructive sleep apnea (OSA) is a prevalent but frequently underdiagnosed type of sleep-disordered breathing. Excessive obesity is a primary reversible risk factor for OSA. A range of novel antidiabetic agents has recently demonstrated p…

BACKGROUND: Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, has demonstrated superior glycemic efficacy in randomized clinical trials. However, real-world data in Indian populations remain limited. OBJECTIVE: The primary objective of this multi…

Metabolic dysfunction-associated fatty liver disease (MAFLD), recently redefined from non-alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L-α-lysophosphatidylinositol/G protein-c…

This study investigated the therapeutic potential of tirzepatide, a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and estrogen deficiency. Four groups were initially established and maintained for 12 weeks unde…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used therapies for cardiovascular risk reduction in type 2 diabetes (T2D). With the emergence of the SURPASS-CVOT trial, tirzepatide (a dual GIP/GLP-1 receptor agonist) has e…

Obesity is a growing public health concern, closely linked to metabolic and cardiovascular complications. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substanti…

INTRODUCTION: Pharmacological therapies are recommended for individuals with obesity. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), and tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GI…

Obesity, diabetes, and menopause impair hypothalamic regulation of energy balance by inducing inflammation, cellular stress, and disruption of neuropeptide signaling. In a female mouse model combining these conditions, we investigated whether tirzepa…

OBJECTIVE: To assess the extent of off-label glucagon-like peptide-1 receptor agonist (GLP-1) prescribing among individuals without diabetes in Medicare Part D. STUDY SETTING AND DESIGN: This cross-sectional study included Medicare Part D beneficiari…

PURPOSE OF REVIEW: Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D). This review summarizes current evidence on the pharmacologic treatment of MASLD, with emphasis on ag…

BACKGROUND: The advent of tirzepatide has transformed obesity care; yet, real-world weight loss outcomes necessarily depend on patient engagement with behavioral support. Digital platforms offering coaching, self-monitoring, and automated feedback ha…